The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are only the beginning.

In this #DoctorPodcasts Episode 149, we sit down with physician, Professor Carel le Roux, a global authority in metabolic medicine, #obesity and #diabetes to discuss the revolutionary shift in anti-obesity medications. We break down the differences between current leading GLP-1 drugs like #Ozempic (semaglutide) and #Mounjaro (tirzepatide), and look ahead to next-generation treatments. Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. We also explore Eli Lilly’s upcoming triple agonist, Retatrutide. If you want to understand the future of weight loss, #MetabolicHealth, and how these drugs target the brain-gut axis, this deep dive is for you.0:00 - Introduction & Guest Overview0:34 - Episode Welcome: Dr. Robert Cykiert0:48 - Entering Dublin: The GLP-1 Breakthrough2:27 - Long-Term Health Hazards of Obesity & Diabetes3:24 - Why Obesity is a Disease of the Brain, Not Willpower4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide)6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic7:50 - The Truth About Visceral vs. Ectopic Fat10:04 - Survodutide Explained: The New Dual Agonist12:45 - Managing Side Effects & Titration Schedules15:37 - Boehringer Ingelheim & the Future of Obesity Medicine16:48 - Retatrutide: Eli Lilly’s New Triple Agonist18:26 - A 30-Second Guide for Doctors & Patients20:11 - Closing Thoughts & Patient Transformations